Bhatt Padmanabh P. 4

What Happened

• Padmanabh P. Bhatt, Senior Vice President of IP and Chief Scientific Officer at Supernus Pharmaceuticals (SUPN), had 1,250 restricted stock units (RSUs vest) on Feb 25, 2026. The RSUs are reported as an award/acquisition (code A) at $0.00.
• The company withheld 650 shares to satisfy tax withholding obligations (code F) at an implied value of $50.69 per share (650 x $50.69 = $32,949). The filing also reports a derivative disposition of 1,250 RSUs related to the vesting/settlement (code D).

Key Details

• Transaction date: 2026-02-25; Form 4 filed: 2026-02-26 (reports the Feb 25 transactions).
• Award: 1,250 RSUs (acquired at $0.00); Tax withholding: 650 shares withheld at $50.69/share for $32,949.
• Filing shows a derivative disposition of 1,250 RSUs associated with the vesting/settlement.
• Shares owned after the transactions: not specified in the provided excerpt of the filing.
• Footnotes: F1 — 650 shares were withheld by the company to satisfy tax withholding on RSU vesting; F2 — each RSU converts into one share upon vesting; F3 — these RSUs vest in four equal annual installments beginning Feb 23, 2024.

Context

• These transactions are routine: RSU vesting and company share withholding to cover taxes (a cashless withholding). The filing does not show an open-market sale or a purchase that would signal active bullish/pessimistic trading by the insider.
• For retail investors, RSU vesting reflects compensation realization, not necessarily a change in the insider’s view of the company. The filing appears timely (filed the day after the reported transactions).